依折麦布联合非诺贝特治疗混合型高脂血症的临床疗效和安全性

The efficacy and safety of ezetimibe combined with fenofibrate for treatment of combined hyperlipidemia

目的观察依折麦布联合非诺贝特治疗混合型高脂血症的临床疗效和安全性。方法选择2012年8月-2014年10月于我院确诊的混合型高脂血症患者128例,随机分为两组各64例。对照组给予非诺贝特（200mg/d）治疗,观察组给予依折麦布（20mg/d）和非诺贝特（200mg/d）联合治疗3个月,检测两组患者治疗前后的总胆固醇（total cholesterol,TC）、三酰甘油（triglyceride,TG）、低密度脂蛋白胆固醇（low density lipoprotein cholesterol,LDL-C）和高密度脂蛋白胆固醇（high density lipoprotein cholesterol,HDL-C）水平,并分析比较治疗效果和安全性。结果 1与治疗前比较,两组患者治疗后的TC、TG、LDL-C水平均明显降低,差异均有统计学意义（均P〈0.05）,而HDL-C水平明显升高,差异亦有统计学意义（P〈0.05）;与对照组比较,联合治疗后观察组的TC、TG、LDL-C水平均降低,差异均有统计学意义（均P〈0.05）,而HDL-C水平增高,差异亦有统计学意义（P〈0.05）。2观察组的总有效率（93.75%）明显高于对照组（76.56%）,差异有统计学意义（P〈0.05）。3观察组出现不良反应的总比例显著低于对照组,差异有统计学意义（P〈0.05）。结论与单用非诺贝特相比,依折麦布联合非诺贝特能更有效地降低混合型高脂血症患者的血脂水平,且安全性较高,弥补了单用贝特类药物降脂的局限性。

Objective To observe the efficacy and safety of ezetimibe combined with fenofibrate in treating patients with combined hyperlipidemia.Methods 128 patients mixed hyperlipidemia were randomly divided into control group given fenofibrate（200mg/d）and observation group given ezetimibe（20mg/d）and fenofibrate（200mg/d）combination.TC,TG,LDL-C,HDL-C and adverse reactions incidence were detected before and 3months after treatment.ResultsTC,TG and LDL-C of the two groups were significantly reduced after treatment（P〈0.05）,while HDL-C level increased（P〈0.05）.Compared with that of the control group,TC,TG and LDL-C of observation group was reduced（P〈0.05）,while HDL-C level increased（P〈0.05）.The total effective rate of observation group was notably increased compared with that of the control group（P〈0.05）.The total proportion of adverse reactions in observation group was markedly decreased compared with that of the control group（P〈0.05）.Conclusion The efficacy of combination of fenofibrate and ezetimibe is significantly better than that of fenofibrate alone in treating combined hyperlipidemia with good safety.